Sign in
Active, not recruitingNo phase

Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder

Key facts

Who runs it
West Virginia University
Where
Morgantown, United StatesSee the site
Trial code
Status
Active, not recruiting
People taking part
4 people enrolled
Started
30 Sept 2019
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • Deep Brain Simulator
Record updated
28 July 2025

Who can take part

Age
21 years to 50 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (31)Hide the full registry criteria

Who can take part

  • Fulfills current DSM-5 (American Psychiatric Association Diagnostic and statistical manual of mental disorders, 5th ed, 2013) diagnostic criteria for OUD (severe) and at least a 5-year history
  • Participants may have comorbid SUD diagnoses at mild, moderate or severe levels, however OUD must be the primary disorder for which the individual is seeking treatment and the other use disorders must occur in the context of relapse
  • Failed at least two levels of treatment (outpatient/Comprehensive Opioid Addiction Treatment (COAT), intensive outpatient/intensive COAT, residential, inpatient, Adult Intensive Outpatient Program (AIOP), Dual Diagnosis Unit (DDU), which included buprenorphine/naloxone
  • At least two overdose survivals or one overdose survival and one life-threatening infectious disease complication with relapse after treatment (e.g., endocarditis with valve repair/replacement) within the past 1 year
  • Family/Social Support/Involvement (as assessed via the Multidimensional Scale of Perceived Social Support)
  • Is able to provide informed consent

Who cannot take part

  • Diagnosis of acute myocardial infarction or cardiac arrest within the previous 6 months
  • Any medical contraindications to undergoing DBS surgery
  • History of previous neurosurgery (brain) or head trauma
  • History of a neurosurgical ablation procedure
  • History of hemorrhagic stroke
  • Past or present diagnosis of schizophrenia, psychotic disorder, bipolar disorder, or untreated depression other than one determined to be substance induced (assessed via SCID-5). Any treated depression has to have been in remission for one year
  • Cluster A or B Personality Disorders
  • Diagnosis of dementia
  • History of neurological disorder
  • History of suicide attempt
  • Parental history of completed suicide
  • Abnormal coagulation lab studies or uncontrolled hypertension
  • Any current CNS infection or infection with the Human Immunodeficiency Virus (HIV)
  • Documentation of MRI abnormality indicative of a neurological condition
  • Conditions requiring diathermy
  • Any evidence of systemic infection
  • Life expectancy of <3 years
  • Medical problems requiring intensive medical or diagnostic management
  • Baseline assessment on the Hamilton Depression Rating Scale (HAMD) of greater than 17 or increased risk of suicide based upon any positive response on the Columbia Suicide Severity Scale
  • Implanted neurostimulators
  • Unable to undergo MR-imaging
  • Substance abuse treatment mandated by court of law
  • Pregnant or planning to become pregnant
  • Anticoagulant treatment
  • Primary language other than English

Where in United States

  • West Virginia University Rockefeller Neuroscience InstituteMorgantown, United States

About the trial

What the trial wants to find out

The purpose of this clinical study is to investigate the safety, tolerability, and feasibility of Deep Brain Stimulation (DBS) of the nucleus accumbens (NAc) and ventral internal capsule (VC) for participants with treatment refractory opioid use disorder (OUD) who have cognitive, behavioral, and functional disability. This study will also provide critical information for planning subsequent clinical trials.

The group in the trial

  • OUD DBSTreatment being tested

    This is a single arm study. Participants will be followed in an inpatient service for two weeks to gather baseline data followed by DBS placement and up to 6 weeks inpatient for clinical stabilization and DBS titration. All participants will then be followed twice a week for 12 weeks in the outpatient setting and then once a week for a total of 52 weeks post-titration.

    Treatment: Deep Brain Simulator

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory
Publications
Record updated
28 July 2025